| UNITED STATES | |
| SECURITIES AND EXCHANGE COMMISSION | |
| Washington, D.C. 20549 | |
| Notice of Effectiveness | |
| Effectiveness Date: | February 3, 2023 |
| Accession Number: | 0001193125-23-022560 | ||||||
| Submission Type: | POS AM | ||||||
| |||||||
| UNITED STATES | |
| SECURITIES AND EXCHANGE COMMISSION | |
| Washington, D.C. 20549 | |
| Notice of Effectiveness | |
| Effectiveness Date: | February 3, 2023 |
| Accession Number: | 0001193125-23-022560 | ||||||
| Submission Type: | POS AM | ||||||
| |||||||
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 2/7/2022 | $28.00 → $30.00 | Buy | HC Wainwright & Co. |
| 11/15/2021 | $27.00 → $28.00 | Buy | HC Wainwright & Co. |
| 8/9/2021 | $30.00 → $27.00 | Buy | HC Wainwright & Co. |
Follows recently announced share acquisitions totaling 2.65 million shares by board members, including Executive Chairman and CEO, Kevin Chin, who purchased the majority of shares Conversion program is aligned with VivoPower's broader capital strategy to minimize dilution following the recent cancellation of the Company's ATM and F-3 registration statement Strategic intent is to further align with shareholder interest, given that unlisted restricted Class B shares are non-tradeable with enhanced voting rights LONDON, March 20, 2026 (GLOBE NEWSWIRE) -- VivoPower PLC (NASDAQ:VIVO) ("VivoPower" or the "Company"), a B Corp-certified global developer and owner of powered land and data cent
Decision reflects commitment to a strategy of non dilutive funding Alternative potential capital sources available at project level LONDON, March 18, 2026 (GLOBE NEWSWIRE) -- VivoPower PLC (NASDAQ:VIVO) ("VivoPower" or the "Company"), a leading B Corp-certified global developer and owner of powered land and data center infrastructure for AI compute applications, today announced that it has formally terminated its Form F-3 registration statement, originally dated December 23, 2025 (the "F-3 Registration Statement"). Effective immediately, the F-3 Registration Statement is no longer available to the Company, and no further sales of ordinary shares will be made pursuant to that filing. Th
CINCINNATI and SEOUL, South Korea, Jan. 31, 2023 /PRNewswire/ -- Meridian Bioscience, Inc. (NASDAQ:VIVO), a leading global provider of diagnostic testing solutions and life science raw materials, and SD Biosensor, Inc. ("SDB") (KOSE: A137310) and SJL Partners LLC ("SJL") (collectively, the "Consortium"), announced today that they have completed the transaction to acquire Meridian. Under the terms of the merger, Meridian shareholders have the right to receive $34.00 per share in cash. Meridian stock will no longer be traded on the NASDAQ Global Select Market. Meridian will cont
HC Wainwright & Co. reiterated coverage of Meridian Bioscience with a rating of Buy and set a new price target of $30.00 from $28.00 previously
HC Wainwright & Co. reiterated coverage of Meridian Bioscience with a rating of Buy and set a new price target of $28.00 from $27.00 previously
HC Wainwright & Co. reiterated coverage of Meridian Bioscience with a rating of Buy and set a new price target of $27.00 from $30.00 previously
For Immediate Release: December 10, 2021 The U.S. Food and Drug Administration today announced the following actions taken in its ongoing response effort to the COVID-19 pandemic: On December 9, 2021, the FDA updated the SARS-CoV-2 Viral Mutations: Impact on COVID-19 Tests web page to share the latest information. The update added new information about the Meridian Bioscience, Inc. Revogene SARS-CoV-2 test, inc
4 - MERIDIAN BIOSCIENCE INC (0000794172) (Issuer)
4 - MERIDIAN BIOSCIENCE INC (0000794172) (Issuer)
4 - MERIDIAN BIOSCIENCE INC (0000794172) (Issuer)
15-12G - MERIDIAN BIOSCIENCE INC (0000794172) (Filer)
10-Q - MERIDIAN BIOSCIENCE INC (0000794172) (Filer)
EFFECT - MERIDIAN BIOSCIENCE INC (0000794172) (Filer)
CINCINNATI, Dec. 2, 2021 /PRNewswire/ -- Meridian Bioscience, Inc. (NASDAQ:VIVO), a leading global provider of diagnostic testing solutions and life science raw materials, announced today that Bryan Baldasare, Executive Vice President, Chief Financial Officer, and Secretary, will retire from Meridian effective December 31, 2021. The Company is engaging an executive search firm in the recruitment of a new chief financial officer. The Company appointed Julie Smith to the position of Senior Vice President, Controller, effective December 6, 2021, and principal accounting officer, effective January 1, 2022.
CINCINNATI, Nov. 24, 2021 /PRNewswire/ -- Meridian Bioscience, Inc. (NASDAQ:VIVO), a leading global provider of diagnostic testing solutions and life science raw materials, announced today that David Phillips, Chairman of the Board of Directors, will retire from the Board of Directors and not seek re-election when his term ends in January 2022. The Board of Directors will elect a new chair when Mr. Phillips' term expires and will not replace the vacated seat, which will reduce the number of directors to eight. Mr. Phillips joined the Meridian Board of Directors in 2000 and ha
Shareholders to Receive $34.00 Per Share in Cash, Providing Immediate, Compelling and Certain Value Transaction Follows Deliberate Review, Including Outreach to Potential Strategic and Financial Partners CINCINNATI and SEOUL, South Korea, July 7, 2022 /PRNewswire/ -- Meridian Bioscience, Inc. ("Meridian" or the "Company") (NASDAQ:VIVO), a leading global provider of diagnostic testing solutions and life science raw materials, and SD Biosensor, Inc. ("SDB") (KOSE: A137310) and SJL Partners LLC ("SJL") (collectively, the "Consortium") announced today that they have entered into a definitive merger agreement whereby a newly formed affiliate vehicle of the Consortium will acquire Meridian in an a
CINCINNATI, May 6, 2022 /PRNewswire/ -- Meridian Bioscience, Inc. (NASDAQ:VIVO) today announced financial results for the second quarter ended March 31, 2022. Second Quarter Fiscal 2022 Highlights (Comparison to Second Quarter Fiscal 2021): Consolidated net revenues totaled $111.2 million, the highest in Company history, with both segments ahead of expectationsLife Science segment delivered record net revenues of $70.1 millionDiagnostics segment net revenues increased 29% year-over-year to a record $41.1 millionLaunched Lyo-Ready™ sample specific master mixes for bloodResumed
CINCINNATI, Ohio, May 2, 2022 /PRNewswire/ -- Meridian Bioscience, Inc. (NASDAQ:VIVO), a leading global provider of diagnostic testing solutions and life science raw materials, announced today that it has acquired, through its subsidiary Meridian Life Science, Inc., substantially all of the assets of EUPROTEIN Inc. The transaction closed on April 30, 2022. EUPROTEIN Inc. offers custom development and production of high-quality bioresearch reagents, with a particular focus on human and other mammalian proteins and recombinant monoclonal antibodies. This acquisition will help
SC 13G/A - MERIDIAN BIOSCIENCE INC (0000794172) (Subject)
SC 13D/A - MERIDIAN BIOSCIENCE INC (0000794172) (Subject)
SC 13G/A - MERIDIAN BIOSCIENCE INC (0000794172) (Subject)